10-Q: Septerna Q3 2025: Novo Deal Fuels Profitability, New Drugs Advance

Septerna reported a net income of $8.2 million for Q3 2025, primarily driven by a $195 million upfront payment from Novo Nordisk and a $12.5 million milestone from Vertex, while advancing new drug candidates SEP-479 and SEP-631.

Summary

• Septerna, Inc. reported a net income of $8,173,000 for the three months ended September 30, 2025, a significant improvement from a net loss of $20,523,000 in the same period last year.
• Revenue for Q3 2025 surged to $21,495,000, up from $176,000 in Q3 2024, primarily due to the Novo Collaboration Agreement.
• For the nine months ended September 30, 2025, the net loss decreased to $38,141,000 from $51,130,000 in the prior year period.
• Cash, cash equivalents, and marketable securities totaled $561,600,000 as of September 30, 2025, which is believed to be sufficient to fund operations for at least 12 months, extending into 2029.
• The company received a one-time, non-refundable upfront payment of $195,000,000 in July 2025 from Novo Nordisk for an exclusive collaboration on oral small molecule therapies for metabolic-related diseases.
• A $12,500,000 milestone payment was received in August 2025 from Vertex Pharmaceuticals for an asset purchase agreement.
• The Phase 1 clinical trial for SEP-786 was discontinued in February 2025 due to hyperbilirubinemia observations, leading to the selection of SEP-479 as a new PTH1R development candidate.
• SEP-479 showed promising preclinical data with no observed hyperbilirubinemia, and a Phase 1 clinical trial is planned for the first half of 2026.
• The Phase 1 clinical trial for SEP-631, an MRGPRX2 negative allosteric modulator for chronic spontaneous urticaria, commenced in August 2025, with initial data expected in the first half of 2026.
• Research and development expenses increased to $24,264,000 in Q3 2025 from $17,832,000 in Q3 2024, and to $65,723,000 for 9M 2025 from $46,020,000 for 9M 2024, driven by increased program costs and headcount.
• General and administrative expenses also rose to $7,117,000 in Q3 2025 from $4,894,000 in Q3 2024, and to $20,884,000 for 9M 2025 from $10,948,000 for 9M 2024, due to increased headcount, IT, legal, and public company operating costs.

Sentiment

Score: 8

Explanation: The company achieved profitability in Q3 2025 due to significant collaboration payments, substantially improving its cash position and extending its runway. While one program (SEP-786) was discontinued, a promising next-generation candidate (SEP-479) has been identified and is progressing, alongside another clinical trial (SEP-631). The financial strength and pipeline advancement, despite the inherent risks of biotech, indicate a strong positive momentum.

Positives

• Achieved net income of $8,173,000 for Q3 2025, a significant turnaround from a net loss of $20,523,000 in Q3 2024.
• Revenue dramatically increased to $21,495,000 in Q3 2025 from $176,000 in Q3 2024, primarily driven by the Novo Collaboration Agreement.
• Secured a substantial $195,000,000 upfront payment from Novo Nordisk for an exclusive collaboration on metabolic-related diseases.
• Received a $12,500,000 milestone payment from Vertex Pharmaceuticals for an asset purchase agreement.
• Successfully identified and advanced SEP-479 as a new PTH1R development candidate for hypoparathyroidism, showing promising preclinical data without the hyperbilirubinemia issues of its predecessor, SEP-786.
• Initiated a Phase 1 clinical trial for SEP-631 for chronic spontaneous urticaria, marking progress in the pipeline.
• Cash, cash equivalents, and marketable securities of $561,600,000 as of September 30, 2025, provide sufficient liquidity for at least the next 12 months, extending into 2029.
• Net cash provided by operating activities was $125,177,000 for the nine months ended September 30, 2025, a significant improvement from $46,512,000 used in the prior year period.

Negatives

• Incurred an accumulated deficit of $156,515,000 as of September 30, 2025, indicating historical and ongoing losses.
• Discontinued the Phase 1 clinical trial for SEP-786 due to observations of hyperbilirubinemia, representing a setback for the initial PTH1R program.
• Research and development expenses continue to increase, reaching $65,723,000 for the nine months ended September 30, 2025, reflecting high costs associated with drug development.
• General and administrative expenses also significantly increased, reaching $20,884,000 for the nine months ended September 30, 2025, due to business growth and public company operating costs.
• The company expects to require substantial additional funding to support continuing operations and growth strategy beyond the current liquidity runway.

Risks

• Disruptions at U.S. government agencies like the FDA, SEC, and USPTO due to staffing reductions, funding shortages, or government shutdowns could hinder product development, regulatory approvals, and business operations.
• Unfavorable macroeconomic conditions, political instability, and geopolitical events (e.g., economic downturns, capital market disruptions, high inflation, international tariffs, military conflicts) could adversely affect business, financial condition, and stock price.
• Healthcare legislative reform measures, such as the Inflation Reduction Act of 2022 (IRA) and recent Executive Orders on drug pricing, may negatively impact the demand for product candidates, pricing, revenue generation, and profitability.
• Changes in U.S. tax law, including provisions related to the capitalization and amortization of research and development expenses (e.g., Section 174 of the IRC, H.R.1), may materially adversely affect cash flow and financial results.
• Proposed legislation like the BIOSECURE Act or similar amendments in the National Defense Authorization Act could restrict the ability to purchase services or products from, or collaborate with, certain Chinese biotechnology companies, potentially impacting supply chains or partnerships.
• The company has incurred significant losses since inception and expects to incur further losses as it continues research and development activities, requiring additional financing.
• The successful development and commercialization of product candidates are highly uncertain, with numerous risks associated with preclinical and clinical development, regulatory approval, and manufacturing.

Future Outlook

The company plans to initiate a Phase 1 clinical trial for SEP-479 in the first half of 2026, pending successful completion of remaining preclinical studies, drug product manufacturing, and regulatory submissions. Initial SAD/MAD data for the SEP-631 Phase 1 clinical trial is anticipated in the first half of 2026. The company expects to continue incurring significant and increasing expenditures for several years as it advances product candidates, expands its pipeline, and operates as a public company, and will require substantial additional funding.

Management Comments

• "We are advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs."
• "Our proprietary Native Complex Platform is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates."
• "We plan to initiate a Phase 1 clinical trial for SEP-479 in the first half of 2026, pending the successful completion of all remaining preclinical studies, drug product manufacturing, and regulatory submissions."
• "We anticipate initial SAD/MAD data [for SEP-631] to be announced in the first half of 2026."
• "We expect to continue to incur significant and increasing expenditures for the next several years as we continue to invest in research and development activities related to developing our product candidates."
• "We believe our cash, cash equivalents and marketable securities of $561.6 million as of September 30, 2025 will be sufficient to fund our operations and capital expenditure requirements at least into 2029."

Industry Context

Septerna operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on G protein-coupled receptor (GPCR) drug discovery. The collaboration with Novo Nordisk for metabolic-related diseases, including GLP-1, GIP, and glucagon receptors, aligns with a major industry trend towards addressing widespread conditions like obesity and type 2 diabetes, where GPCR targets are increasingly recognized for their therapeutic potential. The discontinuation of SEP-786 highlights the inherent risks and high attrition rates in early-stage drug development, while the rapid advancement of SEP-479 demonstrates the company's platform agility in identifying new candidates. The increasing R&D and G&A expenses are typical for a clinical-stage biotech company expanding its pipeline and operating as a public entity. The mention of healthcare legislative reforms and potential tariffs on pharmaceutical imports reflects broader industry-wide pressures on drug pricing and supply chain localization.

Comparison to Industry Standards

• The company's focus on GPCRs and oral small molecules is a well-established but highly competitive area in drug discovery, with many large pharmaceutical companies and biotechs (e.g., Amgen, Eli Lilly, Pfizer, Vertex Pharmaceuticals) having active GPCR programs.
• The collaboration with Novo Nordisk, a leader in diabetes and obesity care (e.g., Ozempic, Wegovy GLP-1 agonists), is a strong validation of Septerna's Native Complex Platform and its potential to generate novel candidates for metabolic diseases. This partnership positions Septerna favorably compared to smaller biotechs that lack such significant external validation and funding.
• The discontinuation of SEP-786 due to hyperbilirubinemia is a common occurrence in early clinical development, where safety and tolerability issues frequently arise. The swift identification and advancement of SEP-479 as a next-generation candidate, with improved safety profile in preclinical studies, demonstrates a responsive development strategy, which is crucial in the high-risk biotech industry.
• The cash runway "at least into 2029" with $561,600,000 in cash, cash equivalents, and marketable securities, following the IPO and Novo upfront payment, is a strong position for a clinical-stage biotech, providing a longer runway than many peers at a similar stage. This compares favorably to many early-stage biotechs that often have 12-24 months of cash.
• The significant increase in R&D expenses (up $19,703,000 for 9M 2025) and G&A expenses (up $9,936,000 for 9M 2025) is typical for a company transitioning from preclinical to clinical stages and operating as a public entity, aligning with industry trends for growing biotechs.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceeding that is expected to have a material adverse effect on its business, financial condition, or results of operations.
• Acknowledges that litigation can have an adverse impact regardless of outcome due to defense and settlement costs, diversion of management resources, and other factors.

Related Party Transactions

• Third Rock Ventures, LLC (TRV), a holder of more than 5% of outstanding capital stock, provides consulting services; no fees were incurred in the nine months ended September 30, 2025.
• A TRV Board Member (former interim Chief Medical Officer) has a separate consulting agreement with cash compensation, with immaterial fees in Q3 2025 and $100,000 in 9M 2025.

Stakeholder Impact

• Shareholders: Positive impact from improved financial results (net income, increased cash), validation from Novo Nordisk collaboration, and pipeline progression. Potential dilution from future equity offerings is a risk.
• Employees: Increased headcount to support business growth and R&D activities, indicating job stability and growth opportunities. Stock-based compensation plans (2024 Plan, 2024 ESPP) provide incentives.
• Customers/Partners (Novo Nordisk, Vertex): Strong collaboration with Novo Nordisk is progressing with four R&D programs. Vertex milestone payment indicates successful asset transfer.
• Creditors: Improved liquidity and cash position enhance the company's ability to meet short-term obligations.
• Patients: Advancement of SEP-479 for hypoparathyroidism and SEP-631 for chronic spontaneous urticaria offers potential new therapeutic options for unmet medical needs.

Next Steps

• Complete remaining preclinical studies, drug product manufacturing, and regulatory submissions for SEP-479.
• Initiate Phase 1 clinical trial for SEP-479 in the first half of 2026.
• Announce initial SAD/MAD data for SEP-631 Phase 1 clinical trial in the first half of 2026.
• Continue to advance the TSHR NAM program towards development candidate selection.
• Continue to advance discovery-stage programs across multiple therapeutic areas.
• Continue to invest in the Native Complex Platform.
• Seek additional financing through equity offerings, debt financings, or collaborations to support future operations and growth.

Key Dates

Recommendation

The company demonstrated strong financial performance in Q3 2025, driven by significant collaboration revenue and a milestone payment, which substantially improved its cash position and extended its operational runway. The advancement of new drug candidates (SEP-479, SEP-631) is positive for the pipeline. However, the discontinuation of SEP-786 highlights the inherent risks in drug development, and the company still faces an accumulated deficit and will require future financing. While the recent financial results are encouraging, the long-term success hinges on clinical trial outcomes and regulatory approvals, which remain highly uncertain. Therefore, a "hold" recommendation is appropriate, acknowledging the positive developments while maintaining caution due to the early stage of clinical programs and future funding needs.

Keywords

Biotechnology, GPCR, Drug Discovery, Clinical-stage, Metabolic Diseases, Hypoparathyroidism, Chronic Spontaneous Urticaria, SEP-479, SEP-631, Novo Nordisk, Vertex Pharmaceuticals, SEC Filing, 10-Q, Pharmaceuticals, Native Complex Platform, Oral Small Molecule, Drug Development, Clinical Trials, Financial Results, Biopharma